Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)

Inclusion Criteria:

1. Women aged from 18 to 70 years;

2. Histologically proven invasive unilateral breast cancer (regardless of the type);

3. Initial clinical condition compatible with complete initial resection;

4. No residual macro or microscopic tumor after surgical excision;

5. Beginning of chemotherapeutic treatment no later than day 42 after the initialsurgery;

6. positive lymph node or negative lymph node with tumor size > 1.0cm

7. Patient presenting one of the following criteria (reviewed before randomization byreferent pathologist): Triple negative （ER-PR-Her-2-） Hormone receptor negativity is defined as ER<1%, PR<1% (IHC), HER2 negativity is defined as IHC 0-1+, or [IHC 2+ and FISH or CISH negative].

8. No clinically or radiologically detectable metastases (M0);

9. No peripheral neuropathy > 1;

10. WHO Performance status (ECOG) of 0 or 1;

11. Adequate recovery from recent surgery (at least one week must have elapsed from thetime of a minor surgery (excluding breast biopsy); at least three weeks for majorsurgery);

12. Adequate hematological function (neutrophil count ³ 2x109/l, platelet count ³ 100x 109/l, Hemoglobin > 9 g/dl);

13. Adequate hepatic function: ASAT and ALAT ≤ 3 ULN alkaline phosphatases ≤ 2.5 ULN,totalbilirubin ≤ 1,5 ULN;

14. Adequate renal function: serum creatinine ≤ 1 ULN;

15. Patients accepting contraception intake during the overall length of treatment if ofchildbearing potential;

16. Adequate cardiac function, LEVF value > 50% by Muga scan or echocardiography;

17. Signed written informed consent.

Exclusion Criteria:

1. Bilateral breast cancer or patient with controlateral DCIS;

2. Any metastatic impairment, including homolateral sub-clavicular nodeinvolvement,regardless of its type;

3. Any T4 lesion (UICC1987) (cutaneous invasion, deep adherence, inflammatory breastcancer);

4. ER+ or PR+ or Her-2 overexpression

5. Any clinically or radiologically suspect and non-explored damage to the controlateralbreast;

6. Any chemotherapy, hormonal therapy or radiotherapy before surgery;

7. Previous cancer (excepted cutaneous baso-cellular epithelioma or uterin peripheralephitelioma) in the preceding 5 years, including invasive controlateral breast cancer;

8. Patients already included in another therapeutic trial involving an experimental drug;

9. Patients with other concurrent severe and/or uncontrolled medical disease or infectionwhich could compromise participation in the study;

10. LEVF < 50% (MUGA scan or echocardiography);

11. Clinically significant cardiovascular disease (e.g. unstable angina, congestive heartfailure, uncontrolled hypertension (>150/90), myocardial infarction or cerebralvascular accidents) within 6 months prior to randomization;

12. Known prior severe hypersensitivity reactions to agents containing Cremophor EL;

13. Women of childbearing potential who are unwilling or unable to use an acceptablemethod to avoid pregnancy for the entire study period and up to 8 weeks aftertreatment completion;

14. Women who are pregnant or breastfeeding. Adequate birth control measures should betaken during study treatment phase;

15. Women with a positive pregnancy test en enrollment or prior to study drugadministration;

16. Patients with any psychological, familial, sociological or geographical conditionpotentially hampering compliance with the study protocol and follow-up schedule; thoseconditions should be discussed with the patient before registration in the trial;

17. Individual deprived of liberty or placed under the authority of a tutor.